

CONTENTS

Preface.....	1
Introduction.....	3

FIRST PART **AUTOMATED PHARMACOLOGICAL SCREENING**

Chapter 1 - The pharmacological screening process: the small molecule, the biological screen, the robot, the signal and the information	7
<i>Eric MARÉCHAL - Sylvaine ROY - Laurence LAFANECHÈRE</i>	
1.1. Introduction	7
1.2. The screening process: technological outline.....	8
1.2.1. Multi-well plates, robots and detectors	8
1.2.2. Consumables, copies of chemical libraries and storage	10
1.2.3. Test design, primary screening, hit-picking, secondary screening	10
1.3. The small molecule: overview of the different types of chemical library	12
1.3.1. The small molecule	12
1.3.2. DMSO, the solvent for chemical libraries.....	12
1.3.3. Collections of natural substances	12
1.3.4. Commercial and academic chemical libraries.....	14
1.4. The target, an ontology to be constructed	14
1.4.1. The definition of a target depends on that of a bioactivity.....	14
1.4.2. Duality of the target: molecular entity and biological function	15
1.4.3. An ontology to be constructed	16
1.5. Controls	17
1.6. A new discipline at the interface of biology, chemistry and informatics: chemogenomics	17
1.7. Conclusion.....	18
1.8. References	19

Chapter 2 - Collections of molecules for screening: example of the french national chemical library	23
<i>Marcel HIBERT</i>	
2.1. Introduction	23
2.2. Where are the molecules to be found?	25
2.3. State of progress with the European Chemical Library	27
2.4. Perspectives	28
2.5. References	28

Chapter 3 - The miniaturised biological assay: constraints and limitations 29*Martine KNIBIEHLER*

3.1. Introduction	29
3.2. General procedure for the design and validation of an assay	30
3.2.1. Choice of assay	31
3.2.2. Setting up the assay	33
3.2.3. Validation of the assay and automation	35
3.3. The classic detection methods	36
3.4. The results	36
3.4.1. The signal measured: increase or decrease?	36
3.4.2. The information from screening is managed on three levels	37
3.4.3. Pharmacological validation	40
3.5. Discussion and conclusion	40
3.6. References	41

Chapter 4 - The signal: statistical aspects, normalisation, elementary analysis 43*Samuel WIECZOREK*

4.1. Introduction	43
4.2. Normalisation of the signals based on controls	44
4.2.1. Normalisation by the percentage inhibition	44
4.2.2. Normalisation resolution	44
4.2.3. Aberrant values	46
4.3. Detection and correction of measurement errors	48
4.4. Automatic identification of potential artefacts	49
4.4.1. Singularities	49
4.4.2. Automatic detection of potential artefacts	50
4.5. Conclusion	52
4.6. References	52

Chapter 5 - Measuring bioactivity: K_i , IC_{50} and EC_{50} 55*Eric MARÉCHAL*

5.1. Introduction	55
5.2. Prerequisite for assaying the possible bioactivity of a molecule: the target must be a limiting factor	55
5.3. Assaying the action of an inhibitor on an enzyme under Michaelian conditions: K_i	56
5.3.1. An enzyme is a biological catalyst	57
5.3.2. Enzymatic catalysis is reversible	57
5.3.3. The initial rate, a means to characterise a reaction	59
5.3.4. Michaelian conditions	59
5.3.5. The significance of K_m and V_{max} in qualifying the function of an enzyme	60
5.3.6. The inhibited enzyme: K_i	60
5.4. Assaying the action of a competitive inhibitor upon a receptor: IC_{50}	62
5.5. Relationship between K_i and IC_{50} : the CHENG-PRUSOFF equation	63
5.6. EC_{50} : a generalisation for all molecules generating a biological effect (bioactivity)	64
5.7. Conclusion	64
5.8. References	65

**Chapter 6 - Modelling the pharmacological screening:
controlling the processes and the chemical, biological and experimental information..... 67***Sylvaine ROY*

6.1. Introduction	67
6.2. Needs analysis by modelling.....	68
6.3. Capture of the needs	69
6.4. Definition of the needs and necessity of a vocabulary common to biologists, chemists and informaticians	69
6.5. Specification of the needs	69
6.5.1. Use cases and their diagrams	70
6.5.2. Activity diagrams	72
6.5.3. Class diagrams and the domain model.....	73
6.6. Conclusion.....	78
6.7. References	78

Chapter 7 - Quality procedures in automated screening..... 79*Caroline BARETTE*

7.1. Introduction	79
7.2. The challenges of quality procedures.....	79
7.3. A reference guide: the ISO 9001 Standard.....	80
7.4. Quality procedures in five steps	82
7.4.1. Assessment	82
7.4.2. Action plan - planning.....	83
7.4.3. Preparation	83
7.4.4. Implementation.....	83
7.4.5. Monitoring.....	83
7.5. Conclusion.....	84
7.6. References	84

SECOND PART**HIGH-CONTENT SCREENING AND STRATEGIES IN CHEMICAL GENETICS****Chapter 8 - Phenotypic screening with cells and forward chemical genetics strategies..... 87***Laurence LAFANECHÈRE*

8.1. Introduction	87
8.2. The traditional genetics approach: from phenotype to gene and from gene to phenotype.....	88
8.2.1. Phenotype	88
8.2.2. Forward and reverse genetics	89
8.3. Chemical genetics	89
8.4. Chemical libraries for chemical genetics	90
8.4.1. Chemical library size.....	91
8.4.2. Concentration of molecules.....	91
8.4.3. Chemical structure diversity.....	91
8.4.4. Complexity of molecules	93

8.4.5. Accessibility of molecules to cellular compartments	93
8.4.6. The abundance of molecules	94
8.4.7. The possibility of functionalizing the molecules	94
8.5. Phenotypic tests with cells	94
8.6. Methods to identify the target	96
8.7. Conclusions	99
8.8. References	99

Chapter 9 - High-content screening in forward (phenotypic screening with organisms) and reverse (structural screening by NMR) chemical genetics 103

Benoît DÉPREZ

9.1. Introduction	103
9.2. Benefits of high-content screening.....	104
9.2.1. Summarised comparison of high-throughput screening and high-content screening	104
9.2.2. Advantages of high-content screening for the discovery of novel therapeutic targets	104
9.2.3. The nematode <i>Caenorhabditis elegans</i> : a model organism for high-content screening.....	105
9.2.4. Advantages of high-content screening for reverse chemical genetics and the discovery of novel bioactive molecules	108
9.3. Constraints linked to throughput and to the large numbers	110
9.3.1. Know-how	110
9.3.2. Miniaturisation, rate and robustness of the Assays	110
9.3.3. Number, concentration and physicochemical properties of small molecules ..	111
9.4. Types of measurement for high-content screening	111
9.4.1. The critical information needed for screening	111
9.4.2. Raw, numerical results	111
9.4.3. Results arising from expert analyses	112
9.5. Conclusion.....	112
9.6. References	112

Chapter 10 - Some principles of Diversity-Oriented Synthesis..... 113

Yung-Sing WONG

10.1. Introduction	113
10.2. Portrait of the small molecule in DOS	114
10.3. Definition of the degree of diversity (DD).....	116
10.3.1. Degree of diversity of the building block	116
10.3.2. Degree of stereochemical diversity	118
10.3.3. Degree of regiochemical diversity	119
10.3.4. Degree of skeletal diversity	121
10.4. Divergent multi-step DOS by combining elements of diversity	124
10.5. Convergent DOS: condensation between distinct small molecules	127
10.6. Conclusion.....	130
10.7. References	130

THIRD PART

TOWARDS AN IN SILICO EXPLORATION OF CHEMICAL AND BIOLOGICAL SPACES

Chapter 11 - Molecular descriptors and similarity indices..... 135*Samia ACI*

11.1. Introduction.....	135
11.2. Chemical formulae and computational representation.....	136
11.2.1. The chemical formula: a representation in several dimensions	137
11.2.2. Molecular information content.....	137
11.2.3. Molecular graph and connectivity matrix	139
11.3. Molecular descriptors.....	140
11.3.1. 1D descriptors	141
11.3.2. 2D descriptors	141
11.3.3. 3D descriptors	144
11.3.4. 3D <i>versus</i> 2D descriptors?	146
11.4. Molecular similarity	147
11.4.1. A brief history	147
11.4.2. Properties of similarity coefficients and distance indices	147
11.4.3. A few similarity coefficients.....	148
11.5. Conclusion.....	148
11.6. References	150

Chapter 12 - Molecular lipophilicity: a predominant descriptor for QSAR..... 153*Gérard GRASSY - Alain CHAVANIEU*

12.1. Introduction.....	153
12.2. History.....	153
12.3. Theoretical foundations and principles of the relationship between the structure of a small molecule and its bioactivity	154
12.3.1. QSAR, QPAR and QSPR.....	154
12.3.2. Basic equation of a QSAR study.....	155
12.4. Generalities about lipophilicity descriptors	155
12.4.1. Solubility in water and in lipid phases: conditions for bioavailability.....	155
12.4.2. Partition coefficients	156
12.4.3. The partition coefficient is linked to the chemical potential.....	156
12.4.4. Thermodynamic aspects of lipophilicity	157
12.5. Measurement and estimation of the octanol/water partition coefficient.....	158
12.5.1. Measurement methods	158
12.5.2. Prediction methods.....	160
12.5.3. Relationship between lipophilicity and solvation energy: LSER	163
12.5.4. Indirect estimation of partition coefficients from values correlated with molecular lipophilicity.....	163
12.5.5. Three-dimensional approach to lipophilicity	165
12.6. Solvent systems other than octanol/water.....	166
12.7. Electronic parameters.....	167
12.7.1. The HAMMETT parameter, σ	167
12.7.2. SWAIN and LUPTON parameters	168

12.8. Steric descriptors	169
12.9. Conclusion.....	169
12.10. References	169

Chapter 13 - Annotation and classification of chemical space in chemogenomics 171

Dragos HORVATH

13.1. Introduction.....	171
13.2. From the medicinal chemist's intuition to a formal treatment of structural information	171
13.3. Mapping structural space: predictive models.....	174
13.3.1. Mapping structural space	174
13.3.2. Neighbourhood (similarity) models	175
13.3.3. Linear and non-linear empirical models	178
13.4. Empirical filtering of drug candidates.....	180
13.5. Conclusion.....	181
13.6. References	181

Chapter 14 - Annotation and classification of biological space in chemogenomics..... 185

Jordi MESTRES

14.1. Introduction.....	185
14.2. Receptors.....	186
14.2.1. Definitions.....	186
14.2.2. Establishing the 'RC' nomenclature	187
14.2.3. Ion-channel receptors.....	188
14.2.4. G protein-coupled receptors.....	189
14.2.5. Enzyme receptors	190
14.2.6. Nuclear receptors	190
14.3. Enzymes	191
14.3.1. Definitions.....	191
14.3.2. The 'EC' nomenclature	192
14.3.3. Specialised nomenclature.....	193
14.4. Conclusion.....	193
14.5. References	194

Chapter 15 - Machine learning and screening data..... 197

Gilles BISSON

15.1. Introduction.....	197
15.2. Machine learning and screening.....	199
15.3. Steps in the machine-learning process	202
15.3.1. Representation languages.....	203
15.3.2. Developing a training set	205
15.3.3. Model building.....	206
15.3.4. Validation and revision	207
15.4. Conclusion.....	209
15.5. References and internet sites	209

Chapter 16 - Virtual screening by molecular docking.....	213
<i>Didier ROGNAN</i>	
16.1. Introduction	213
16.2. The 3 steps in virtual screening.....	213
16.2.1. Preparation of a chemical library	213
16.2.2. Screening by high-throughput docking.....	216
16.2.3. Post-processing of the data.....	218
16.3. Some successes with virtual screening by docking.....	220
16.4. Conclusion.....	221
16.5. References	222

APPENDIX

BRIDGING PAST AND FUTURE?

Chapter 17 - Biodiversity as a source of small molecules for pharmacological screening: libraries of plant extracts.....	227
<i>Françoise GUERITTE, Thierry SEVENET, Marc LITAUDON, Vincent DUMONTET</i>	
17.1. Introduction	227
17.2. Plant biodiversity and North-South co-development	229
17.3. Plant collection: guidelines	230
17.4. Development of a natural-extract library	231
17.4.1. From the plant to the plate	231
17.4.2. Management of the extract library	231
17.5. Strategy for fractionation, evaluation and dereplication	233
17.5.1. Fractionation and dereplication process.....	233
17.5.2. Screening for bioactivities.....	235
17.5.3. Some results obtained with specific targets	236
17.5.4. Potential and limitations.....	239
17.6. Conclusion.....	240
17.7. References	240
Glossary	241
The authors	253

Chemogenomics and Chemical Genetics
A User's Introduction for Biologists, Chemists and
Informaticians

MARECHAL, E.; Roy, S.; Lafanechère, L. (Eds.)

2011, XI, 256 p., Hardcover

ISBN: 978-3-642-19614-0